
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934**

Date of Report: July 30, 2026

Commission File Number: 001-36891

Collectis S.A.
(Exact Name of registrant as specified in its charter)

**8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

<u>Exhibit</u>	<u>Title</u>
----------------	--------------

99.1	Press Release dated July 30, 2026
----------------------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Collectis S.A.

(Registrant)

Date: July 30, 2026

/s/ André Choulika

André Choulika
Chief Executive Officer

Collectis to Report Second Quarter Financial Results on August 6, 2026

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Collectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.

The press release will be available in the Investors section of Collectis' website: <https://www.collectis.com/en/investors/press-releases/>

Collectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@collectis.com

About Collectis

Collectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Collectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Collectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Collectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

To find out more, visit www.collectis.com and follow Collectis on LinkedIn and X.

For further information on Collectis, please contact:

Media contacts:

Pascalyné Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@collectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@collectis.com

Attachment

- Q2 2026 announcement PR_ENGLISH (<https://ml.globenewswire.com/Resource/Download/f560a55d-b231-4ae6-b032-b17f8846ec16>)